About Vaxart
Vaxart is a company based in San Francisco (United States) founded in 2004. Vaxart has raised $57.97 million across 11 funding rounds from investors including HHS, Care Capital Management and Care Capital. The company has 115 employees as of December 31, 2024. Vaxart offers products and services including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform. Vaxart operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Biological E, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vaxart, Inc.
-
Annual Revenue
$28.7 M (USD)288.94as on Dec 31, 2024
-
Net Profit
-$66.95 M (USD)18.82as on Dec 31, 2024
-
EBITDA
-$61.89 M (USD)21.5as on Dec 31, 2024
-
Total Equity Funding
$57.97 M (USD)
in 11 rounds
-
Latest Funding Round
$18.4 M (USD), Series C
Jan 08, 2015
-
Investors
HHS
& 5 more
-
Employee Count
115
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxart
Vaxart is a publicly listed company on the OTC with ticker symbol VXRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vaxart
Vaxart offers a comprehensive portfolio of products and services, including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.
Vaccines delivered as oral pills for immunity against viral diseases.
Platform for developing oral recombinant vaccines.
Platform focused on enhancing mucosal immune responses.
People of Vaxart
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxart
Vaxart has successfully raised a total of $57.97M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $18.4 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vaxart
Vaxart has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Care Capital Management and Care Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Life sciences startups are funded by a non-profit angel network.
|
Locked | Locked | Locked |
Investor details for Vaxart
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vaxart
Investment portfolio details for Vaxart
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vaxart
Detailed financials for Vaxart
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vaxart Comparisons
Peer comparison for Vaxart
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vaxart
Vaxart operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
Detailed competitors of Vaxart
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vaxart
Complete news archive for Vaxart
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxart
Vaxart was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Vaxart is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Vaxart is a funded company, having raised a total of $57.97M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Vaxart is 115.
Annual revenue of Vaxart is $28.7M as on Dec 31, 2024.
Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.
Vaxart's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Vaxart offers Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.
Yes, Vaxart is publicly traded on OTC under the ticker symbol VXRT.
Vaxart has 6 investors. Key investors include HHS, Care Capital Management, Care Capital, Quantum Technology Partners, and Life Science Angels.
The ticker symbol of Vaxart is VXRT on OTC.